Skip to Content

Nymox Nears Completion of Latest U.S. Study of NX-1207 for BenignProstatic Hyperplasia

HASBROUCK HEIGHTS, NJ (April 15, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company’s latest multi-center U.S. Phase 2 study of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH) is nearing completion.  The Company anticipates the reporting of final results and statistical analysis for the study within the next few weeks.

The results of the blinded clinical trials to date have shown that men treated with NX-1207 reported statistically significant improvement in BPH symptoms 3 months after a single NX-1207 treatment.  In two multi-center Phase 2 U.S. prospective randomized blinded clinical trials, the aggregated mean improvement in the Primary Endpoint of BPH Symptom Score for 2.5 mg NX-1207 was 10.3 points or a 44% improvement in Symptom Score.  To date, subjects treated with NX-1207 have reported no serious side effects from the treatment, including no (0%) significant sexual side effects.

Results of 5 follow-up studies of available subjects from NX-1207 clinical trials have provided evidence of durable benefits from NX-1207 treatment for up to 3 ½ years from the date of treatment.

NX-1207 treatment is administered by intraprostatic injection of a single dose by a urologist in an office setting. The entire procedure lasts on average 5-10 minutes, with the injection taking 1-2 minutes, and does not require anesthesia or catheterization.

BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age. BPH causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems, and can cause acute urinary retention requiring immediate medical attention.

More information about Nymox is available at, email:, or 800-936-9669.

This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

For Further Information Contact:  
Roy Wolvin
Nymox Pharmaceutical Corporation

Posted: April 2008